Dr Philip McMillan
Physician, Lead COVID-19 autoimmune researcher, #1 Amazon Best Seller, Dementia Authority, International Keynote Speaker


About
Experienced physician and researcher with a pioneering approach to understanding COVID-19 and reversing dementia. I was the first to propose the ground-breaking theory of autoimmunity to ACE-2 in COVID-19 (April 2020). I share my passion for advancing science and health through being an International Keynote Speaker (UK, Singapore, Japan, China, Ireland, Canada and Italy) and engaging LinkedIn Live interviews and insightful posts.
To explore my latest research and gain a deeper understanding of the COVID-19 autoimmune theory, visit COVID-19 STORM (Spike Triggered AutOimmune Response Mechanism), where you’ll find valuable insights into how my innovative work is shaping the future of medical science.

Innovative Solutions
Our focus is on medical research to find innovative solutions for a selection of common diseases as well as strategies to manage them. Vejon Media is a social media business focused on raising the profile of health-related companies. Vejon Conferences bring experts together to share information on research, strategies and products related to the understanding and management of diseases.
Dementia Crowd Research
Dementia Crowd Research recognizes that many solutions for dementia lie with caregivers, and it aims to empower them and make a positive impact.
McMillan Research
McMillan Research, takes a unique approach to medical research, applying the fundamentals of physiology and pathology to understand disease
Vejon MED Newsletter
Vejon MED is an easy-to-read information resource for curious minds. Complemented by original content, we scour dozens of sources for the latest medical news so you don’t have to.
Kickstarter Campaigns
We thank everyone who contributed to our ‘Humming Heroes’ Kickstarter. Your support resulted in a unique educational resource and reinforces the value of protecting health.
A Unique Approach to Medical Research
Early stage research is underway on Type ll diabetes, macular degeneration and obesity. As this work progresses, these diseases may become the focus of new health projects.
